Muhamed Baljevic MD

Muhamed Baljevic, MD, is Associate Professor of Medicine at Vanderbilt University Medical Center. Dr. Baljevic is Director of Plasma Cell Disorders Research at Vanderbilt-Ingram Cancer Center, where he is also Director of the Vanderbilt Amyloidosis Multidisciplinary Program (VAMP). He also serves as disease team lead for plasma cell dyscrasias and lymphomas.

Dr. Baljevic completed his medical education at the Weill Cornell Medical College in Qatar, where he graduated with MD Honors in Research. During his medical training, Dr. Baljevic spent a year working in the Ansary Center for Stem Cell Therapeutics at the Weill Cornell Medical College of Cornell University. He subsequently completed his internal medicine internship and residency training at New York-Presbyterian Hospital Weill Cornell Medical Center and his hematology and medical oncology training at The University of Texas MD Anderson Cancer Center. Concurrently with his fellowship, Dr. Baljevic pursued a master’s degree in clinical and translational research at The University of Texas Graduate School of Biomedical Sciences.

Dr. Baljevic’s clinical and research interests are in the field of multiple myeloma, AL Amyloidosis, and other plasma cell disorders. His investigative focus is on better understanding of mechanisms of proteasome inhibitor resistance, the importance of augmented post-transplant immune reconstitution in transplant recipients, and the role of genomic events such as chromosomal alterations and gene mutations in the transformation of premalignant plasma cell conditions to plasma cell malignant states. As institutional cellular therapy investigator in plasma cell malignancies, he aims to explore novel mechanistic approaches in the treatment of high unmet needs in relapsed and refractory MM and AL Amyloidosis, including those patients with multi-class resistant or refractory disease.

Dr. Baljevic is a member of the American Society of Clinical Oncology (ASCO), the American Society of Hematology, the American Association for Cancer Research (AACR), the European Hematology Association, and the American Society of Transplantation and Cellular Therapy. He also serves on the editorial board for Frontiers in Oncology. Dr. Baljevic has received several scholarships, honors, and awards, including the Celgene Future Leaders in Hematology Award for Clinical Research and the ASCO/AACR Workshop on Methods in Clinical Cancer Research. He also has contributed to publications in prestigious journals including Nature Medicine, Cancer Cell, Journal of Clinical Investigation, Circulation Research, Hematology/Oncology Clinics of North America, as well as several book chapters by invitation.

Dr. Baljevic is a member of the NCCN Multiple Myeloma/Systemic Light Chain Amyloidosis/Waldenström Macroglobulinemia Panel.